See more : Scatec ASA (SCATC.OL) Income Statement Analysis – Financial Results
Complete financial analysis of PPD, Inc. (PPD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PPD, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- RVH Inc. (6786.T) Income Statement Analysis – Financial Results
- Provenance Gold Corp. (PVGDF) Income Statement Analysis – Financial Results
- Bhagyanagar Properties Limited (BHAGYAPROP.NS) Income Statement Analysis – Financial Results
- Kunlun Energy Company Limited (KUNUF) Income Statement Analysis – Financial Results
- SDI Group plc (SDIIF) Income Statement Analysis – Financial Results
PPD, Inc. (PPD)
About PPD, Inc.
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|
Revenue | 4.68B | 4.03B | 3.75B | 3.00B | 2.68B |
Cost of Revenue | 2.88B | 2.41B | 2.27B | 1.54B | 1.39B |
Gross Profit | 1.80B | 1.62B | 1.47B | 1.46B | 1.29B |
Gross Profit Ratio | 38.42% | 40.24% | 39.32% | 48.80% | 48.25% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
Operating Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
Cost & Expenses | 4.17B | 3.61B | 3.35B | 2.74B | 2.37B |
Interest Income | 0.00 | 0.00 | 5.45M | 3.55M | 2.51M |
Interest Expense | 216.93M | 311.74M | 263.62M | 253.89M | 203.29M |
Depreciation & Amortization | 279.12M | 264.83M | 258.97M | 279.07M | 260.49M |
EBITDA | 668.54M | 627.35M | 666.36M | 544.62M | 630.92M |
EBITDA Ratio | 14.28% | 15.56% | 17.77% | 18.15% | 23.55% |
Operating Income | 509.43M | 418.49M | 402.24M | 261.33M | 314.26M |
Operating Income Ratio | 10.88% | 10.38% | 10.73% | 8.71% | 11.73% |
Total Other Income/Expenses | -321.88M | -359.21M | -255.61M | -244.86M | -147.37M |
Income Before Tax | 187.55M | 59.28M | 146.63M | 16.47M | 166.89M |
Income Before Tax Ratio | 4.01% | 1.47% | 3.91% | 0.55% | 6.23% |
Income Tax Expense | 18.81M | 2.96M | 39.58M | -284.36M | -15.96M |
Net Income | 153.69M | 47.82M | 104.19M | 296.03M | 183.10M |
Net Income Ratio | 3.28% | 1.19% | 2.78% | 9.86% | 6.83% |
EPS | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
EPS Diluted | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
Weighted Avg Shares Out | 346.68M | 339.43M | 324.30M | 325.04M | 324.22M |
Weighted Avg Shares Out (Dil) | 346.68M | 339.43M | 324.30M | 325.86M | 324.30M |
PPD Named Clinical Research Company of the Year for Second Consecutive Year
PPD Announces Third Quarter 2021 Earnings Conference Call
PPD Announces Third Quarter 2021 Earnings Conference Call
PPD Announces Third Quarter 2021 Earnings Conference Call
Society for Clinical Research Sites Names PPD Winner of Prestigious Eagle Award
Society for Clinical Research Sites Names PPD Winner of Prestigious Eagle Award
Aethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical Programs
PPD Earns Gold Award for Excellence in Employee Learning and Development
PPD Earns Gold Award for Excellence in Employee Learning and Development
PPD Receives Award Recognizing Employee Talent Development
Source: https://incomestatements.info
Category: Stock Reports